Boehringer Ingelheim Vetmedica has launched Buscopan 20mg/ml injection, an antispasmodic treatment for use in cases of equine colic, and an aid to the symptomatic treatment of calf scour.
A sister product to Buscopan Compositum which contains both an antispasmodic and a non-steroidal component, Buscopan 20 contains only the antispasmodic component - hyoscine butylbromide.
Craig Beck, equine sales and marketing manager at Boehringer Ingelheim Vetmedica said: "Our customers have been telling us for some time that they would really welcome a Buscopan formulation without an NSAID for use in horses and cattle. I'm pleased to say that it's finally here and I'm sure that Buscopan 20 will be a very welcome addition to the armoury of both equine and cattle practitioners."
Buscopan 20 is supplied in a 50ml multi-dose bottle, and is available in veterinary wholesalers now.
For further information, please call 01344 746959.
The study, titled ‘Physics of animal health: On the mechanobiology of hoof growth and form’, represents the fruit of a collaboration between researchers in equine medicine, maths, physics and stem cell biology. It was conducted by the School of Veterinary Medicine and Science at University of Nottingham in collaboration with the Waltham Centre for Pet Nutrition and the Royal Veterinary College.
Lead author Dr Cyril Rauch said: "With new scientific inputs from physics, mathematics and biology, this study provides an entirely new paradigm regarding hard growing tissues such as the horse hoof, which can be applied across cattle, sheep and other species, to unify a set of apparently disparate conditions and clarify the roles of physics and/or biology."
Using hooves from horses euthanased for non-research purposes, the study revealed how it is possible for the hoof growth rate to be greater than the potential proliferation rate of epithelial cells. It also explained how the synthesis of the hoof capsule starts from the coronet and that the soft papillae undergo gradual transition through three interpapillary regions into hard keratinised tissue.
Mathematics, physics and cell biology were then used in the study to explain and describe how the dorsal hoof wall can grow in a curved manner rather than the usual straight manner as a result of faster growth from the coronary band at the quarters compared to the toe region.
Evaluation of the feet from live underweight and obese subjects (assessed using Body Condition Scoring) allowed the influence of body weight on the balances of the stresses affecting hoof growth to be evaluated. The results suggest that being proportionally heavier may promote straighter hoof growth and that being too lean may precipitate poor hoof growth and the development of a hoof with a dorsal curved shape.
The study also showed that a high concentration of insulin stimulated equine progenitor keratinocytes (the outermost layer of cells on the hoof wall) to grow in culture. If this also happens chronically within the live animal, it is possible that it could affect the growth stresses within the hoof and so promote a dorsal curved hoof shape.
Co-author Nicola Menzies-Gow said: "These results taken together can explain how the hoof grows and how it is possible for it to develop a dorsal curvature. However, it should be acknowledged that this does not take into account the genetic or metabolic influences on hoof growth nor the role of hoof trimming and shoeing in maintaining a mechanically healthy hoof. It is appreciated that the underlying biology of hoof growth remains an essential factor for hoof pathologies."
Dr Cyril Rauch continued: “Given that the hoof is a weight bearing element it is essential to untangle the biology from the physics in this system; only then can meaningful biological and/or physical causes be prescribed for particular hoof shape. Removing the cause(s) when physically or biologically possible is essential to resolve hoof conditions."
Reference
With fewer than 72 female Suffolk Punches remaining in the UK and fewer than 300 in the world, every female born is vital to the survival of this endangered British horse.
In 2019 Tullis Matson, owner and managing director of Stallion AI Services, saw an opportunity to use a new technological advancement in the sex sorting of equine semen to provide a lifeline to Britain’s critically endangered rare and native horses.
Tullis said: “To be able to use our reproduction expertise in this way, to help preserve an irreplaceable part of our magnificent heavy horse heritage is something we have been working towards for many years. The challenges have been great and many, but watching the birth of this beautiful, healthy filly foal was a truly magical experience."
The sex sorting project uses specialist equipment to sex sort the semen prior to insemination based on the difference in DNA content between X and Y bearing spermatozoa.
Ruby, the Suffolk Punch mare and Holbeach Iggy, the Suffolk stallion were selected and matched based on their genetics as part of a project between The Rare Breed Survival Trust and Nottingham Trent University that uses pedigree information to enable the breeding of small populations in a way that minimises the risk of inbreeding and genetic decline.
Christopher Price, Chief Executive of the Rare Breed Survival Trust, said: “This is tremendous news for anyone concerned with the conservation of our native equines. The most effective way of increasing the population size of this very rare breed is by increasing the number of fillies being born.
“The project demonstrates the viability of using new techniques for selecting female foals in order to increase the breeding population much more rapidly than could be achieved through relying on traditional methods. We hope it will prove to be a model for more projects in the future.”
Pfizer Animal Health has launched Zylexis for horses, the first and only immunomodulator licensed in the UK to reduce the clinical signs of equine respiratory disease associated with over-crowding and stress.
Zylexis contains inactivated parapox ovis virus (iPPOV), a super-antigen which Pfizer says boosts a horse's immune system to reduce the effects of infectious respiratory disease1,2 - bridging the gap between potential and performance.
According to the company, Zylexis acts by stimulating the horse's non-specific immune system, inducing antiviral interferons and interleukins and stimulating innate immune cells. In this way it bridges the gap until the horse's adaptive immune system can develop a pathogen-specific response.3-5
Pfizer highlights research which has shown a 40.3% reduction in the clinical signs and duration of respiratory disease in young horses under conditions of crowding and stress and a significant reduction of purulent nasal discharge when using Zylexis.6,7 No local or systemic adverse events were observed in a 999 dose study.8
Wendy Talbot, National Veterinary Manager at Pfizer, said: "Zylexis has been licensed in the States and in Germany for a number of years. We believe Zylexis plays a pivotal role in helping to minimise the severity of respiratory disease outbreaks in these countries, therefore helping to maintain performance potential. It's a very welcome addition to the medicine box of UK vets."
The administration of Zylexis is recommended as a course of three single dose intramuscular injections on days 0, 2 and 9. The first dose should be administered shortly before the over-crowding or stressful situation.
References
Supplies of the vaccine, which is indicated for the active immunisation for horses against equine arteritis, ran low at the end of last year when Zoetis' existing stock was due to expire without any new stock in place.
For further information, contact your Zoetis Account Manager or the Zoetis Technical Team on customersupportUK@zoetis.com or 0845 300 9084 choosing option 1.
The apple-flavoured, gastro-resistant granules can be mixed with dry feed to make administration easier for owners.
Animalcare says that up to 37% of leisure horses and 93% of race horses are reported to be affected by gastric ulcers1, for which the most prescribed treatment is omeprazole.
Equizol’s granule formulation has been developed to support owners who find syringe administration difficult or wasteful. It is presented in packs of 28 sachets, each containing sufficient omeprazole to treat 200 kg body weight. Owners mix the appropriate number of sachets into a small amount of the horse’s feed.
Animalcare Product Manager James Beaumont said: “Offering innovative product solutions which better meet our customer’s needs is our goal and Equizol is a perfect example. Our established equine healthcare range includes products for pain management, infusion therapy and microchips. Now, with the launch of Equizol, we are offering an innovative, easy-to-use and cost-effective solution to the common problem of gastric ulcers, based on tried and trusted omeprazole. We are delighted to add it to our range.”
Boehringer Ingelheim Vetmedica has launched Equisolon 33 mg/g oral powder, the first licensed oral prednisolone for the alleviation of inflammation associated with recurrent airway obstruction (RAO), otherwise known as heaves, in horses.
Clare Turnbull, equine brand and technical manager at Boehringer Ingelheim Vetmedica said: "Oral glucocorticoids are sometimes necessary for treating the inflammation associated with RAO. We feel it is important that when our customers need to use prednisolone for their cases, there is an equine specific product available to them that is easy to dispense and administer."
The company says Equisolon should be used in combination with environmental measures to treat RAO.
For further information on Equisolon, contact your Boehringer Ingelheim Vetmedica equine representative or call +44 (0)1344 746959.
The company says Dormazolam works in synergy with other induction agents to provide an extended duration of anaesthesia without adversely affecting the quality of recovery 2,3,5.
Benzodiazepines are commonly incorporated into anaesthetic regimens to alleviate issues seen with the administration to ketamine alone2,3,4, including inadequate muscle relaxation2,3,4, anaesthesia not lasting long enough2 and induction failure2.
Despite the issues caused by the sole use of ketamine, it remains the primary anaesthetic induction agent of choice for more than 90% of equine vets2.
Dechra Brand Manager Emma Jennings said: “Using Dormazolam as part of an equine anaesthesia protocol will give optimal general anaesthetic conditions every time, including a rapid onset of action1.
"Anaesthetic co-induction with ketamine and midazolam has been shown to provide a superior quality of anaesthesia compared to ketamine alone3 and midazolam is equally as effective as diazepam when used as a co-induction agent alongside ketamine4. It also cuts down on the number of ketamine ‘top-up’ doses required compared to using ketamine3 alone.
"Additional benefits include no clinically significant differences in cardiopulmonary function1 or recovery times1 between midazolam and diazepam and it can be mixed in the same syringe as ketamine for ease of use4.”
Emma added: “The introduction of Dormazolam provides an exciting new option for equine vets. It delivers enhanced anaesthetic and surgical conditions by improving anaesthetic induction quality2,3,4 and giving better surgical relaxation scores2,3,4. It also reduces involuntary movements because, as a co-induction agent, midazolam only causes minimal cardiovascular and pulmonary depression2,4.”
Dormazolam is available in a 20 ml vial. It has a shelf life of four years and a broached shelf life of 28 days.
For more information, visit: www.dechra.co.uk/therapy-areas/equine/anaesthesia/analgesia.
References:
The debate, which was described as 'robust but good-humoured', was moderated by BEVA past-President Madeleine Campbell, sole partner at Hobgoblins Equine Reproduction Centre.
Keith Chandler, former BEVA President and member of the acquisitions team at Independent Vet Care and Karl Holliman, partner and director at Cliffe Veterinary group and past chairman of XL Equine, argued for corporatisation.
Their supporting witnesses were Lesley Barwise Munro of AlNorthumbria vets which was sold to CVS in 2015 and Julian Samuelson a former managing partner of Bell Equine, which was sold to CVS earlier this year.
In the opposing corner were Andrew Harrison, a partner at Three Counties Equine Hospital and Tim Greet, who recently retired as an equine partner at Rossdales.
Their supporting witnesses were Louise Radford MRCVS, who now works in the pharmaceutical industry and Nenad Zillic, partner at the Barn Equine Surgery.
As the moderator called 'seconds out', opinion was relatively evenly divided, with 44% of the audience agreeing with the motion and 56% disagreeing.
The pro corporatisation team advocated that obvious commercial and business advantages, together with the scale and diversity of a corporate, can give vets greater potential for a more flexible career path and advancement within the industry, and a more sustainable working career in equine practice.
Karl Holliman pointed out that corporates enable greater purchasing power, better health and safety resources, improved career structure and the freedom for employed vets to focus on clinical expertise rather than becoming bogged down with practice management.
Keith Chandler went on to argue that selling to a corporate is a solution to the problem of succession planning. In a climate of unwillingness for younger vets to buy in to practice, selling allows partners to realise the value they've built up and release that equity to do something else.
This is all very well, said Tim Greet, on the anti corporatisation panel, but the good reputation the profession currently enjoys is based on service to clients and above all the animals in our care. Clinical rather than commercial elements drive practice and partners are light on their feet and can respond quickly to decisions without referring to "a ponderous corporate hierarchy".
Tim also argued that clients like continuity and the quickest way to lose them would be to send in different vets. A bespoke approach to client care was needed rather than hard targeting.
Andrew Harrison went on to suggest that the only vets who really benefit from selling out are those who have one eye on retirement. Younger partners may be able to pay off the loan they took out to buy into practice in the first place but are then likely to take a considerable drop in salary and be given a middle management job, moving from the "pilot seat into the passenger seat." He argued that young vets cannot afford to buy into practices because the industry is being "fuelled by the corporates who are falling over themselves competing to buy equine practices and squeezing out our fellow professionals."
Pro corporatisation witness Julian Samuelson maintained that since Bell Equine has been sold to CVS there has been no change to client service, no restrictions on clinical performance and that no targets have been imposed to achieve set revenues.
Anti-corporatisation witness Louise Radford made the point that big corporates could exert pressure on pharmaceutical companies to drive down prices, which would reduce their capacity to invest in research and development trials and CPD, to the ultimate detriment of the veterinary industry.
The session closed with 72% of the audience disagreeing with the motion Corporatisation is inevitable and will benefit vets and their clients.
BEVA President Jon Pycock said: "Whether we like it or not corporatisation of equine practices is on the rise. But it shouldn’t mean that the future isn’t going to be viable for independents too as there is a role for both to co-exist. Importantly, this should mean that vets and their clients will both continue to have choices."
Zoetis has launched UlcerGold (omeprazole) for the treatment - and prevention of recurrence - of gastric ulcers in horses and foals, presented in a syringe suitable for foals from four weeks of age and horses from 70 to 700kg.
Equine Gastric Ulceration Syndrome (EGUS) is a serious and common condition affecting horses and foals.2,3 Approximately 90% of racehorses, 60% of performance horses, 37% of leisure horses and 50% of foals have been shown to be affected.2,4,5 The condition is associated with injury to the mucosa of the oesophagus, stomach and duodenum, with prolonged exposure to gastric acid thought to be the primary cause.2,3 Risk factors include stress, intense exercise, a high-grain diet, intermittent feeding and illness.2,3 EGUS can have a profound impact on a horse's condition and performance and can ultimately be life threatening, especially in foals.3,5 It is a challenging condition to diagnose as the clinical signs are often vague and not always present.3 Gastroscopy is the only method currently available for a definitive diagnosis and treatment is usually based on acid suppressive therapy to allow ulcer healing.2
UlcerGold is indicated to treat and prevent the recurrence of gastric ulcers in horses, administered once-daily for 28 consecutive days at the full dose of 4mg/kg bodyweight followed by the reduced dose of 1mg/kg bodyweight for a further 28 days.1 It contains omeprazole, a proton pump inhibitor that suppresses gastric acid secretion.1,2 One syringe contains enough UlcerGold for a horse weighing up to 700kg. It can be used for foals as young as four weeks of age that weigh over 70kg and for breeding stallions.
Zoetis says UlcerGold is supported by a comprehensive gastroscope training programme, pricing model, client support and communications plan to ensure that it is a strong asset to veterinary businesses.
Penny McCann, Equine Product Manager, Zoetis UK Ltd, said: "UlcerGold is an exciting addition to our equine POM-V portfolio. We have designed a training, education and business programme to help practices make sure they get the best from our new product, not only in terms of gastric ulceration treatment but also practice health."
Tranquinervin, which contains 10 mg/ml acepromazine, is indicated for anaesthetic premedication, tranquilisation and sedation.
Emma Jennings, Brand Manager at Dechra said: "Tranquinervin provides tranquillisation or a mild sedation for several hours, making it a valuable tool for many day-to-day veterinary scenarios.
"At low doses, acepromazine reduces anxiety which is beneficial for use in horses prior to shoeing or transportation. At higher dose rates, it is an effective sedative for use in situations like dentistry or handling. The relaxant effects also aid examination of the penis in horses and the treatment of tetanus and choke.
"There is also reduced anaesthetic risk reported following sole premedication with acepromazine in healthy horses1."
Tranquinervin is available in a 20 ml vial with a 56 day broached shelf life. It can be used in conjunction with Dechra’s equine anaesthesia and analgesia app which is designed to help you choose optimal anaesthetic protocols and calculate anaesthetic drug doses and administration rates quickly and easily.
For more information, go to: www.dechra.co.uk/products/equine
Founded by Peter Rossdale in Newmarket in 1959, the practice now boasts a team of 50 veterinary surgeons and has established an international reputation for providing world class ambulatory, referral and laboratory services. The team is led by RCVS, European and American recognised veterinary specialists and operates from four sites in Newmarket, Exning, Hertfordshire and Lambourn.
Each year, Rossdales Equine Hospital in Exning hosts a large number of CPD courses which often include internationally recognised guest speakers who lecture alongside Rossdales’ specialist clinicians, with delegates attending from as far afield as Europe, Singapore, Dubai and Australia.
To celebrate the practice’s Diamond anniversary, Rossdales is hosting a special 'Diamond Series' of CPD events in 2019 in addition to its usual programme of educational courses.
Mike Shepherd, Managing Partner at Rossdales, said: "Since the practice was established by Peter Rossdale in 1959, it has always prided itself on clinical research and the willing distribution of this and other information to the veterinary profession. This ‘Diamond Anniversary’ series of CPD events is an initiative that we hope will benefit many of our veterinary colleagues. The first of these special events, the Diamond Series Veterinary Nursing Congress, was held at the beginning of June and was fully subscribed. We’re very pleased by the excellent feedback it generated."
Two further ‘Diamond Series’ events are scheduled, for veterinary surgeons and veterinary students respectively:
The Diamond Series Veterinary Surgeons Congress takes place on Friday,12th and Saturday, 13th July 2019 and is for all veterinary surgeons with an interest in equine or mixed practice. The programme covers a wide area of subjects, with talks provided by 12 veterinary surgeons from Rossdales Equine Hospital and Rossdales Laboratories. It also includes admission to The Moët & Chandon July Festival at Newmarket Racecourse on Saturday, 13th July.
The Diamond Series Undergraduate Congress will take place on Saturday, 10th and Sunday, 11th August 2019. This course is aimed at all current veterinary undergraduates who want to gain more knowledge and experience in the fields of equine veterinary medicine and surgery. There will be talks and presentations from 9 veterinary surgeons from Rossdales Equine Practice, Rossdales Equine Hospital and Rossdales Laboratories. There will also be a course dinner on the Saturday evening.
For more information, visit www.rossdales.com/news-events.
The Care About Cushing’s website is designed to give horse owners the information they need to spot the signs of Cushing's, thereby prompting diagnosis by their veterinary surgeon.
The online resource includes monitoring tools, personalised alerts, owner guides and webinars. It also offers downloadable self-assessment checklists on Cushing’s disease and laminitis to take owners through the signs to look out for.
Owners whose horses have been diagnosed with Cushing’s are encouraged to sign up as a Care About Cushing’s member to keep up-to-date with the latest information about the disease and create a personal profile for their horse in order to monitor progress. One of the membership benefits is an 'ask the expert' section where members can ask questions about Cushing’s disease and laminitis.
The Care About Cushing’s resource supports Boehringer’s ‘Talk About Laminitis’ initiative to raise awareness of the signs of laminitis and its link with Cushing’s disease.
Talk About Laminitis now runs throughout the year and as part of the campaign the laboratory fees for the blood test which detects Cushing’s (the basal ACTH test) are free.
Liz Barrett, equine business head at Boehringer, said: "Our Talk About Laminitis disease awareness initiative has been hugely successful in highlighting the link between laminitis and Cushing’s disease and helping to diagnose Cushing’s. So much so that Cushing’s is now in the top five equine diseases recorded in the UK1."
For further information on Talk About Laminitis or Care About Cushing’s, visit www.talkaboutlaminitis.co.uk, www.careaboutcushings.co.uk or contact your local Boehringer territory manager.
The campaign comprises a series of short videos featuring equine behaviourist Gemma Pearson MRCVS. The videos demonstrate quick and simple ways of teaching horses to be quiet, relaxed and safe for injections, clipping, worming, examinations and other veterinary procedures.
Equine practices can share the video links with clients here.
According to a paper published in the journal Equine Veterinary Education in January, an equine vet may expect to sustain between seven and eight work-related injuries that impede them from practicing, during a 30-year working life.1
This is far a higher figure than other civilian occupations such as the construction industry, prison service and the fire brigade.
Bruising, fracture and laceration to the leg or the head were the most common injuries reported with the main cause being a kick with a hind limb. Nearly a quarter of these reported injuries required hospital admission and 7% resulted in loss of consciousness.
David Mountford, CEO at BEVA said: "Many accidents reportedly occur when vets are trying to work with horses who have learnt to avoid examination or treatment and where handlers are not in full control. Gemma’s work at the Royal (Dick) School of Veterinary Studies and her amazing videos show how a little preparation can have a big impact on horse, owner and vet safety.”
David Catlow, Blue Cross director of clinical services, said: "These videos are a superb resource to help with behaviour training in horses and to help them remain calm and manageable in all sorts of circumstances. Time spent on behaviour training of horses, using positive reinforcement methods such as these, is time well spent for everyone’s safety. Blue Cross invests a great deal of time in behaviour training on the horses we rehome, and it works."
The seven practical videos cover how clients can train and prepare their horse for:
David Mountford added: "These videos make interesting viewing for vets as well as horse owners and build on Gemma’s eBEVA webinar "Practical Equine Behaviour" and the Guidance on Managing Equine Risks that BEVA has produced.”
You can watch the videos here.
Photo: Equine vets Malcolm Morley and Gemma Pearson
To win, OVs are asked to submit a question to a speaker of their choice by Monday 12 August.
The question judged the most interesting will win the free ticket and five runners up will each receive a 50% discounted ticket. In each case, the OV can choose their preferred day to attend.
The full programme can be found at: https://officialvet.com/programme/ and questions can be submitted to enquiries@improve-ov.com or by private message through Facebook at https://www.facebook.com/officialvet/
Improve says this year's speakers will address an increasing threat from notifiable diseases in the UK, with evidence of M. bovis infection linked to a raw pet food diet identified in cats, an outbreak of equine viral arteritis in Dorset and cases of African swine fever recently reported in western Europe. The programme includes small animal and farm animal focused lecture streams on both days, an equine stream on the first day and a series of specialist workshops on the second.
Dr Andrew Soldan (pictured right), Veterinary Director at APHA, said: "Notifiable diseases are an ongoing threat to the health and welfare of animals and our farming industries in the UK. Animal keepers and vets play a vital role in their early detection. We’re particularly concerned by the risk of African swine fever following the disease being found in wild boar in Belgium last year.
"Small animal and mixed practice OVs can help us reduce the risk of ASF infecting UK pigs by informing pig keepers of the risk and advising them of the importance of not feeding kitchen scraps and catering waste to pigs.
"We’re currently in the vector season so bluetongue is another disease to look out for in cattle and sheep. Providing advice to livestock farmers on how they can minimise the risk of its introduction through vaccination and checking the source of imported animals is another important role for OVs."
David Babington MRCVS, Business Development Director at Improve International, said: "OVs play a crucial role in monitoring our exposure to notifiable diseases and in alerting us to possible outbreaks. For this reason, providing a full update on the current disease status is an important element of this year’s programme, though we will also cover other important topics, including illegal puppy imports, pet travel and, inevitably I’m afraid, Brexit."
For more information on the Official Veterinarian Conference and exhibition or to register visit: www.officialvet.com.
Current World Organisation for Animal Health (OIE) recommendations are to include a representative strain from each of the two sublineages of equine influenza virus (EIV) - Florida Clade 1 and Florida Clade 2, to deliver optimum protection.
MSD's study was designed to evaluate the efficacy of Equilis Prequenza, containing whole virus Newmarket/2/93 (European strain) and South Africa/4/03 (Clade1) EIV strains, and an HA canarypox vectored vaccine containing Florida Clade 1 and Clade 2 strains.
Two groups of seven Fjord ponies were vaccinated twice, 4 weeks apart (V1 on day 0 and V2 on day 28). One group was vaccinated with Equilis Prequenza (MSD AH) and one group with ProteqFlu (Boehringer Ingleheim). The protective antibody response was measured and ponies were challenged, along with six unvaccinated control ponies, by experimental infection with Wexford/14 (a heterologous clade 2 strain), 1 20 days (4.5 months) after V2, and clinical signs and virus shedding monitored. EI serology was measured by single radial haemolysis (SRH) and hemagglutination inhibition (HI). Clinical signs and virus shedding (measured by qRT-PCR and egg titration) were compared between groups and with controls.
Vicki Farr, BVetMed MRCVS, equine veterinary advisor at MSD Animal Health said: "Following challenge at 120 days after V2 with Wexford/14, this study demonstrates that both vaccines provide a highly significant degree of protection against clinical signs of EI and viral shedding compared to unvaccinated controls. Although the study was not designed to compare the efficacy of the two vaccines, because of practical limitations on the number of animals and hence low power, there was no evidence of any significant differences between these two groups. There was, however, a trend towards slightly lower clinical score on days 4-8 and reduced virus excretion on days 2-5 in the Equilis Prequenza group compared to the HA canarypox vectored vaccine.”
MSD says Equilis Prequenza offers a broad based approach to immunogenicity by addressing and adapting key areas of an equine influenza vaccine - Matrix-C adjuvant, whole virus antigen and strain; efficacy has been proven through challenge trials and longer term protection confirmed by serology.
Vicki added: "Equilis Prequenza addresses key factors involved in promoting effective immunogenicity. It combines the demonstrated efficacy against challenge, with a current circulating strain with an established safety profile. Equilis Prequenza stimulates active immunity against EI providing the reassurance your clients demand. MSD Animal Health is committed to working with equine practices to improve vaccination rates in at-risk horses."
For more information about the trial results contact your MSD Animal Health account manager.
EnteroZoo is a dietary supplement composed of organic mineral and purified water in a gel suspension. Enteromed says it works by binding bacterial toxins as it passes through the animal's digestive tract, thereby helping to maintain a healthy gut and intestinal balance.
Enteromed says that compared to old classic adsorbents, such as clay or charcoal, EnteroZoo can be used long-term and is gentle on an animal's intestines.
The company points to a new in-vitro study from Brighton University School of Pharmacy & Biomolecular Sciences which has shown that EnteroZoo adsorbs E. coli, Shigella and C. difficile toxins1 – common causes of gastrointestinal infection and diarrhoea.
EnteroZoo is suitable for all animals including pregnant and nursing females. It is tasteless and odourless and the company says animals generally accept it without any problems. It can be administered in various ways: directly into the mouth, mixed into feed, put on a treat, mixed in an appropriate amount of water or administered with a plastic syringe into the oral cavity.
For more information, contact: enterozoo@enteromed.co.uk, or visit: www.enterozoo.co.uk
The company says the new product has been 10 years in development and uses 'Soft Mist' technology - developed originally for human use by its pharma business - to deliver medication deep into the horse's lungs.
The active ingredient in the Aservo EquiHaler is ciclesonide, a corticosteroid that is activated directly in the lung, reducing the lower airway inflammation associated with severe equine asthma and reducing the risks commonly associated with systemic corticosteroids.
The Aservo EquiHaler does not use a propellant, so it does not contribute to greenhouse gas emissions. Boehringer also highlights that it is made from up to 50% recycled materials. In April, the product was awarded a Red Dot Design Award.
Dr Marc Laemmer, Head of Equine in UK & Ireland said: "It's another industry first and is a strong indicator of the commitment that Boehringer Ingelheim has to the health and welfare of horses, and to the investment that we make into continuing to advance therapies through collaboration and innovation.
"We understand that a product launch in this challenging time for the veterinary profession may seem surprising, but we have had such strong demand from equine vets for the product that we have committed to making Aservo EquiHaler available. Out team of territory managers and vet advisers will conduct remote meetings with customers to make sure that they have the information and support they require."
Elanco, a division of Eli Lilly and Company, has launched into the UK companion animal market with a pledge to listen to vets and provide a highly personalised level of support.
The company will initially offer recognised brands such as equine vaccines from the Duvaxyn range, Felocell vaccine for cats and equine wormer Strongid P. It says it is also developing a range of innovative new products designed to address the unmet needs of companion animals, the first of which are expected to be launched during 2011.
Mrs Tina Hunt, a Glasgow Vet School graduate and most recently, Veterinary Business Director at Fort Dodge UK, has been appointed with a remit to build the Elanco Companion Animal Health organisation in the UK. Reporting to Jannes Nijland, Director Elanco Western Europe, she will spearhead the company's growth and relationship building with veterinary practices across the country.
Tina said: "Recent changes in the animal health sector make it an exciting time to be launching a new companion animal brand. The opportunity to be in at the start and to shape a completely new business from scratch was too good to miss. My team shares a passion to combine the best of our experience with new approaches and new ways of working which are more closely attuned to what vets actually want. This means doing things differently and this is a challenge we relish.
We seek a genuine partnership with the profession and look forward to building close, individual relationships with vets and practices, helping them to enable companion animals to live longer, healthier and higher quality lives. While we're a newcomer in this sector, we benefit from the track record and resources available to Elanco, the fifth largest animal company in the world. We're determined to make Elanco Companion Animal Health a trusted and valued partner to vets working in companion animal practice."
Elanco develops and markets products to improve animal health and food-animal production in more than 75 countries. The company employs more than 2,300 people worldwide, with offices in more than 40 countries, and is a division of Eli Lilly and Company, a pharmaceutical corporation. Additional information about Elanco is available at www.elancopet.com and the company can be contacted via email: elancoCAH.uk@lilly.com
Equitop GLME is a palatable, pearl formulation joint supplement developed to support the healthy function of cartilage, joint capsules, tendons and ligaments. It is derived from an active extract of New Zealand Green Lip Mussels - a natural source of glucosaminoglycans (GAGs), chondroitin and essential fatty acids – and is tested free of prohibited substances.
Boehringer says the nutrients in Equitop GLME help to lubricate joints, as well as supporting normal joint function, the stability and elasticity of ligaments and the shock-absorbing properties of cartilage.
Equitop GLME is fed once a day either separately or mixed with feed and one tub will typically last for 30 days and can be used in all horses and ponies.
Dr Amy Scott, brand manager for Equitop GLME at Boehringer Ingelheim, said: "By encompassing Equitop GLME into the Equitop portfolio and launching easy-to-read new packaging, we are enhancing our product offering to both veterinary practices and horse owners."
For more information, contact your Boehringer account manager.
This multimillion pound centre will support the provision of advanced first opinion and referral equine services in the Midlands.
Senior Partner Richard Stephenson said: "It was a great honour and pleasure to have His Royal Highness visit our new premises, and our staff eagerly anticipated meeting Prince Charles and showing him the wonderful facilities we now have."
Amongst these are a Fujifilm SonoSite Edge II portable ultrasound system. Richard added: "Pool House is a well-known practice – we’ve been in existence for over 150 years – and we have developed a reputation as a specialist equine imaging centre, with radiography, ultrasound and MRI capabilities. The new facility has been designed to give us increased theatre capacity and stabling, and we needed an additional ultrasound system to match this expansion."
"The demands of equine practice mean that ultrasound is often required in difficult circumstances, and we need systems that can cope with extreme temperatures, dust, straw, mud, water and the occasional knock. Many pieces of equipment used in veterinary medicine were originally intended for a human clinical environment, so can’t stand up to the rigors of our work – they’re simply not fit for purpose. However, SonoSite systems are perfect for us; they’re robust, highly portable and very intuitive to use, which is important for intermittent ultrasound users."
Licensed for the treatment of severe equine asthma, each Equipred tablet contains 50mg of prednisolone, a larger concentration tablet designed to make dosing easier.
Equipred tablets are available in boxes of 100 tablets and each tablet can be divided into halves and quarters for accurate dosing and precise tapering of the administered dose.
Rosie Naylor, Equine Technical Product Manager at Virbac said: "We are pleased to add Equipred to Virbac’s equine range. The novel 50mg tablet presentation will enable accurate dosing of horses that require orally administered steroid treatment".
For more information, contact your Virbac Territory Manager.
Evidence-Based Veterinary Medicine Matters: Our Commitment to the Future represents the first time that such a broad and influential group has united in support of a single issue in the veterinary profession.
The publication contains a number of case studies which illustrate the impact that evidence can have – and has had – on animal health and welfare. It also provides a rationale for veterinary professionals to contribute to the evidence base and put evidence into practice, to the benefit of animals, owners and veterinary teams themselves.
The signatories to the commitment are:
Animal and Plant Health Agency
British Cattle Veterinary Association
British Equine Veterinary Association
British Small Animal Veterinary Association
British Veterinary Association
British Veterinary Nursing Association
RCVS Knowledge
Royal College of Veterinary Surgeons (RCVS)
Royal Veterinary College
University of Bristol
University of Cambridge
University of Liverpool
University of Nottingham
University of Surrey
Veterinary Policy Research Foundation
No sign of the BAHVS, I see.
Jacqui Molyneux, Chair of the Board of Trustees of RCVS Knowledge, said: "Evidence-Based Veterinary Medicine Matters is a milestone publication for the professions, representing the first time the majority of the key institutions have aligned under the same EBVM banner.
"A celebration of decades of incredible discoveries, achievements and improvements in animal health, it also serves to remind us that even the earliest forms of veterinary medicine were underpinned by evidence."
UK Chief Vet Christine Middlemiss said: "What’s the evidence? An evidence-based approach is vital in all areas of our profession, whatever is keeping you awake at night. For me, it is the threat of African swine fever and avian flu. The evidence I rely on comes from our specialist surveillance monitoring and testing, veterinary epidemiologists and disease modellers. It enables me to make timely, proportionate risk-based decisions that stand up to scrutiny.
"If you are managing veterinary care in practice, the evidence you rely on to underpin your standards of clinical care comes from multiple sources too. Evidence-based veterinary medicine allows us to refine and tailor strategies to be effective and efficient, making full use of existing and new technologies.
"The profession has taken great strides towards embracing evidence-based veterinary medicine and building on this will strengthen the links between clinical decision-making, policy development and future research."
Chris Gush, Executive Director of RCVS Knowledge, added: "We are impressed by the contributions from our co-signatories, which clearly demonstrate the phenomenal impact on patient outcomes that conducting research and using evidence can have. We are also delighted that Sense about Science, a flagbearer for evidence, transparency and rational thinking, has joined with us to highlight the many benefits EBVM can bring.
"The publication also makes a strong case for much-needed funding for research to grow the evidence base, which would put powerful, robust data into the hands of veterinary professionals as they make critical decisions that can affect patient outcomes.
"It is our hope that the calibre, diversity and sheer number of the organisations putting their name to this commitment will galvanise all vets and their teams to expand their use of evidence in practice."
Rebecca Asher, Deputy Director at Sense about Science, said: "This is a showcase of game changers in veterinary care and we hope it will inspire and motivate everyone in the profession.
"We were delighted that RCVS Knowledge approached us to collaborate with them and other leading institutions in the veterinary research community to affirm their commitment to an evidence-based approach to veterinary medicine.
"Everyone expects treatment for humans to be underpinned by evidence. We now expect the same of the whole veterinary community when it comes to the treatment of animals."
The full commitment and portfolio of case studies can be read in Evidence-Based Veterinary Medicine Matters, available for free online: bit.ly/EBVMMatters.
Rominervin contains 10 mg/ml romifidine hydrochloride, equivalent to 8.76 mg romifidine, presented in a 20 ml vial.
It can be used as a sedative to facilitate handling, examination, minor surgical interventions and minor procedures or as a premedication prior to administration of injectable or inhalation anaesthetics.
Rominervin can also be used in combination with synthetic opiates such as butorphanol to provide deeper sedation or analgesia.
Dechra Brand Manager Emma Jennings said: "Rominervin is highly effective as it has a longer duration of action than other alpha-2 agonists1. It starts to work within one to two minutes with maximum sedation achieved between five and 10 minutes.
"It is yet another valuable addition in our equine anaesthesia and analgesia range that has been designed to provide vets with the therapies they need to operate successfully in day-to-day practice."
Rominervin can be used in conjunction with Dechra’s equine anaesthesia and analgesia app, designed to help veterinary professionals choose optimal anaesthetic protocols and calculate anaesthetic drug doses and administration rates.
For more information visit: www.dechra.co.uk/products/equine
VetSurgeon member Andrew Dobson of The Barn Equine and Large Animal Practice in Great Wakering, Essex has won the inaugural Petplan Equine Vet of the Year Award.
Owners and riders all over the UK were invited to send in nominations for this new people's award. A short list of three finalists was then drawn up and the winner selected by an independent panel consisting of Jo Whitaker, brand manager for Petplan Equine; Alison Bridge, editor-in-chief of Horse&Rider magazine; David Stickels, head of fundraising for the AHT, and David Dugdale, president of the British Equine Veterinary Association (BEVA).
Andrew was nominated by a number of his grateful clients and their glowing testimonials impressed the judges enough to give him the edge over his closest rivals for the title.
"This award is intended to recognise the amazing hard work and commitment of people within the equine veterinary profession and those who provide outstanding service to horse owners," explained Jo Whitaker. "We received some very strong nominations and all three finalists are clearly exceptional vets. Andrew Dobson was nominated by a number of his clients and they all stressed his professionalism and devotion to the horses in his care and how he regularly goes beyond the call of duty in making sure that both horses and owners are given the very best treatment."
Suzy Dorey was among the clients to nominate Andrew: "When I came across Andy I realised that he was an old fashioned type of vet and had the time and patience to deal with the horses and just as importantly the clients. I cannot recommend Andy highly enough and would like to see him given recognition of some sort for being a dependable, down-to-earth vet."
Andrew said: "I am absolutely stunned. I'm so honoured and amazed to of received the Petplan Equine Vet of the Year award. I really enjoy what I do and would like thank all my clients, Petplan Equine, the Animal Health Trust and Horse&Rider for their support."